FULC NASDAQ
Fulcrum Therapeutics, Inc.
1W: -1.3%
1M: -4.2%
3M: -0.8%
YTD: -66.2%
1Y: -60.5%
3Y: -19.8%
5Y: -86.6%
$3.69
+0.01 (+0.27%)
Weekly Expected Move ±1.4%
$4
$4
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2022-05-10
Earliest Filing
2025-12-11
Latest Filing
partner: 7
Counterparties (Filed by FULC)
7 relationshipsCompanies named in FULC's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Leerink Partners LLC | — | partner | Underwriter for the public offering of common stock and pre-funded warrants | 2025-12-11 | View |
| Cantor Fitzgerald & Co. | — | partner | Underwriter for the public offering of common stock and pre-funded warrants | 2025-12-11 | View |
| Sanofi | SNYNF | partner | Entered into a collaboration and license agreement for the development and commercialization of losmapimod outside the U | 2024-05-13 | View |
| Genzyme Corporation | — | partner | Wholly-owned subsidiary of Sanofi that is a party to the collaboration and license agreement. | 2024-05-13 | View |
| CAMP4 Therapeutics Corporation | CAMP | partner | Fulcrum received a worldwide exclusive license from CAMP4 for Diamond Blackfan Anemia program rights. | 2023-07-10 | View |
| Children's Medical Center Corporation | — | partner | CAMP4 licensed intellectual property rights under an agreement with CMCC. | 2023-07-10 | View |
| Piper Sandler & Co. | PIPR | partner | Sales agent for at-the-market offering program | 2022-05-10 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-17 | Material Agreement; Unregistered Equity Sales; Change in Control; Officer/Director Change; Regulatio | Agreement | View |
| 2026-08-10 | Officer/Director Change | View | |
| 2026-06-25 | Shareholder Vote | View | |
| 2026-06-11 | Officer/Director Change | View | |
| 2026-06-04 | Exit/Disposal Costs; Other Events | View | |
| 2026-06-01 | Other Events; Exhibits | View | |
| 2026-04-27 | Termination of Agreement; Earnings Release; Officer/Director Change; Exhibits | View | |
| 2026-02-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-12-11 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-12-08 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-10-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-28 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-07-29 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-27 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-04 | Termination of Material Definitive Agreement | View | |
| 2025-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-12-23 | Termination of Material Definitive Agreement; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR